Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Hepatic expression levels of interferons and interferon-stimulated genes in patients with chronic hepatitis C: A phenotype–genotype correlation study

Genes & Immunity volume 16, pages 321–329 (2015)Cite this article

Subjects

Abstract

IFNL4 is linked to hepatitis C virus treatment response and type III interferons (IFNs). We studied the functional associations among hepatic expressions of IFNs and IFN-stimulated genes (ISGs), and treatment response to peginterferon and ribavirin. Type I IFNs (IFNA1, IFNB1), type II (IFNG), type III (IFNL1, IFNL2/3), IFNL4 and ISG hepatic expressions were measured by qPCR from in 65 chronic hepatitis C (CHC) patients whose IFNL4-associated rs368234815 and IFNL3-associated rs12989760 genotype were determined. There was a robust correlation of hepatic expression within type I and type III IFNs and between type III IFNs and IFNL4 but no correlation between other IFN types. Expression of ISGs correlated with type III IFNs and IFNL4 but not with type I IFNs. Levels of ISGs and IFNL2/3 mRNAs were lower in IFNL3 rs12979860 CC patients compared with non-CC patients, and in treatment responders, compared with nonresponders. IFNL4-ΔG genotype was associated with high ISG levels and nonresponse. Hepatic levels of ISGs in CHC are associated with IFNL2/3 and IFNL4 expression, suggesting that IFNLs, not other types of IFNs, drive ISG expression. Hepatic IFNL2/3 expression is functionally linked to IFNL4 and IFNL3 polymorphisms, potentially explaining the tight association among ISG expression and treatment response.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  1. Seeff LB . The history of the "natural history" of hepatitis C (1968-2009). Liver Int 2009; 29 (Suppl 1): 89–99.

    Article  Google Scholar 

  2. Ghany MG, Strader DB, Thomas DL, Seeff LB . Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335–1374.

    Article  CAS  Google Scholar 

  3. Liang TJ, Ghany MG . Current and future therapies for hepatitis C virus infection. N Engl J Med 2013; 368: 1907–1917.

    Article  CAS  Google Scholar 

  4. Liang TJ, Ghany MG . Therapy of Hepatitis C - Back to the Future. N Engl J Med 2014; 370: 2043–2047.

    Article  Google Scholar 

  5. Meissner EG, Wu D, Osinusi A, Bon D, Virtaneva K, Sturdevant D et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest 2014; 124: 3352–3363.

    Article  CAS  Google Scholar 

  6. Meissner EG, Bon D, Prokunina-Olsson L, Tang W, Masur H, O'Brien TR et al. IFNL4-DeltaG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. J Infect Dis 2014; 209: 1700–1704.

    Article  CAS  Google Scholar 

  7. Thomas E, Gonzalez VD, Li Q, Modi AA, Chen W, Noureddin M et al. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology 2012; 142: 978–988.

    Article  CAS  Google Scholar 

  8. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, Filipowicz W et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A. 2008; 105: 7034–7039.

    Article  CAS  Google Scholar 

  9. Chen L, Borozan I, Feld J, Sun J, Tannis LL, Coltescu C et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005; 128: 1437–1444.

    Article  CAS  Google Scholar 

  10. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399–401.

    Article  CAS  Google Scholar 

  11. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105–1109.

    Article  CAS  Google Scholar 

  12. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100–1104.

    Article  CAS  Google Scholar 

  13. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798–801.

    Article  CAS  Google Scholar 

  14. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338–1345 45 e1-7.

    Article  CAS  Google Scholar 

  15. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013; 45: 164–171.

    Article  CAS  Google Scholar 

  16. Bibert S, Roger T, Calandra T, Bochud M, Cerny A, Semmo N et al. IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med 2013; 210: 1109–1116.

    Article  CAS  Google Scholar 

  17. McFarland AP, Horner SM, Jarret A, Joslyn RC, Bindewald E, Shapiro BA et al. The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. Nat Immunol 2014; 15: 72–79.

    Article  CAS  Google Scholar 

  18. Balagopal A, Thomas DL, Thio CL . IL28B and the control of hepatitis C virus infection. Gastroenterology 2010; 139: 1865–1876.

    Article  CAS  Google Scholar 

  19. Park H, Serti E, Eke O, Muchmore B, Prokunina-Olsson L, Capone S et al. IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection. Hepatology 2012; 56: 2060–2070.

    Article  CAS  Google Scholar 

  20. Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139: 499–509.

    Article  CAS  Google Scholar 

  21. Dill MT, Duong FH, Vogt JE, Bibert S, Bochud PY, Terracciano L et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2011; 140: 1021–1031.

    Article  CAS  Google Scholar 

  22. Abe H, Hayes CN, Ochi H, Maekawa T, Tsuge M, Miki D et al. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. J Hepatol 2011; 54: 1094–1101.

    Article  CAS  Google Scholar 

  23. Abe H, Hayes CN, Ochi H, Tsuge M, Miki D, Hiraga N et al. Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state. J Med Virol 2011; 83: 1597–1607.

    Article  CAS  Google Scholar 

  24. Asahina Y, Tsuchiya K, Muraoka M, Tanaka K, Suzuki Y, Tamaki N et al. Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response. Hepatology 2012; 55: 20–29.

    Article  CAS  Google Scholar 

  25. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010; 52: 1888–1896.

    Article  CAS  Google Scholar 

  26. Noureddin M, Wright EC, Alter HJ, Clark S, Thomas E, Chen R et al. Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology 2013; 58: 1548–1557.

    Article  CAS  Google Scholar 

  27. Rotman Y, Noureddin M, Feld JJ, Guedj J, Witthaus M, Han H et al. Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. Gut 2014; 63: 161–169.

    Article  CAS  Google Scholar 

  28. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100–1104.

    Article  CAS  Google Scholar 

  29. Meier V, Mihm S, Ramadori G . Interferon-alpha therapy does not modulate hepatic expression of classical type I interferon inducible genes. J Med Virol 2008; 80: 1912–1918.

    Article  CAS  Google Scholar 

  30. Sarasin-Filipowicz M, Wang X, Yan M, Duong FH, Poli V, Hilton DJ et al. Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43. Mol Cell Biol 2009; 29: 4841–4851.

    Article  CAS  Google Scholar 

  31. Lanford RE, Guerra B, Lee H, Chavez D, Brasky KM, Bigger CB . Genomic response to interferon-alpha in chimpanzees: implications of rapid downregulation for hepatitis C kinetics. Hepatology 2006; 43: 961–972.

    Article  CAS  Google Scholar 

  32. Fujiwara D, Hino K, Yamaguchi Y, Kubo Y, Yamashita S, Uchida K et al. Type I interferon receptor and response to interferon therapy in chronic hepatitis C patients: a prospective study. J Viral Hepat 2004; 11: 136–140.

    Article  CAS  Google Scholar 

  33. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, MacDonald MR et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006; 131: 1887–1898.

    Article  Google Scholar 

  34. Duong FH, Trincucci G, Boldanova T, Calabrese D, Campana B, Krol I et al. IFN-lambda receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN-lambda3 genotype and with nonresponsiveness to IFN-alpha therapies. J Exp Med 2014; 211: 857–868.

    Article  CAS  Google Scholar 

  35. Feld JJ, Nanda S, Huang Y, Chen W, Cam M, Pusek SN et al. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology 2007; 46: 1548–1563.

    Article  CAS  Google Scholar 

  36. Randall G, Chen L, Panis M, Fischer AK, Lindenbach BD, Sun J et al. Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection. Gastroenterology 2006; 131: 1584–1591.

    Article  CAS  Google Scholar 

  37. Amanzada A, Kopp W, Spengler U, Ramadori G, Mihm S . Interferon-lambda4 (IFNL4) transcript expression in human liver tissue samples. PloS One 2013; 8: e84026.

    Article  Google Scholar 

  38. Petta S, Cabibbo G, Enea M, Macaluso FS, Plaia A, Bruno R et al. Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2014; 59: 1692–1705.

    Article  Google Scholar 

  39. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 2008; 26: 317–325.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This research was supported by the Intramural Research Program of the NIDDK, NIH.

Author information

Author notes

  1. M Noureddin and Y Rotman: These authors contributed equally to this work.

Authors and Affiliations

  1. Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA

    M Noureddin, Y Rotman, F Zhang, H Park, B Rehermann, E Thomas & T J Liang

  2. Division of Gastroenterology, Cedars-Sinai Medical Center, Los Angeles, CA, USA

    M Noureddin

  3. Immunology Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA

    H Park & B Rehermann

Authors
  1. M Noureddin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y Rotman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B Rehermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T J Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T J Liang.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on Genes and Immunity website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Noureddin, M., Rotman, Y., Zhang, F. et al. Hepatic expression levels of interferons and interferon-stimulated genes in patients with chronic hepatitis C: A phenotype–genotype correlation study. Genes Immun 16, 321–329 (2015). https://doi.org/10.1038/gene.2015.11

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/gene.2015.11

This article is cited by

Search

Advanced search

Quick links